S
ITOS

SignatureFD’s iTeos Therapeutics ITOS Stock Holding History

SignatureFD’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8
Closed -$48 – 3343
2025
Q1 		$48 Hold
8
– – ﹤0.01% 3288
2024
Q4 		$61 Sell
8
-5,026
-100% -$43.2K ﹤0.01% 3260
2024
Q3 		$51.4K Sell
5,034
-113
-2% -$1.72K ﹤0.01% 1559
2024
Q2 		$76.4K Sell
5,147
-102
-2% -$1.46K ﹤0.01% 1298
2024
Q1 		$71.6K Buy
5,249
+768
+17% +$8.37K ﹤0.01% 1370
2023
Q4 		$49.1K Buy
4,481
+3,265
+269% +$32.4K ﹤0.01% 1475
2023
Q3 		$13.3K Buy
1,216
+55
+5% +$703 ﹤0.01% 2054
2023
Q2 		$15.4K Buy
1,161
+869
+298% +$12.4K ﹤0.01% 2024
2023
Q1 		$3.97K Buy
292
+155
+113% +$2.78K ﹤0.01% 2594
2022
Q4 		$2.68K Sell
137
-45
-25% -$879 ﹤0.01% 2709
2022
Q3 		$3K Buy
182
+168
+1,200% +$3.87K ﹤0.01% 2652
2022
Q2 		$0 Buy
+14
New +$332 ﹤0.01% 3228
2022
Q1 		– Sell
-5
Closed – – 3230
2021
Q4 		$0 Buy
+5
New +$166 ﹤0.01% 3182
2021
Q3 		– Sell
-30
Closed -$1K – 3119
2021
Q2 		$1K Buy
+30
New +$715 ﹤0.01% 2744

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SignatureFD's ITOS Position: Q2 2025 in Review

SignatureFD sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 8 shares — an estimated $48 sold.

SignatureFD first reported a position in ITOS in Q2 2021 and held it in 14 quarters. The position peaked at $76.4K in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • SignatureFD reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SignatureFD sold 8 iTeos Therapeutics shares in Q2 2025, an estimated $48.
  • SignatureFD first reported a position in iTeos Therapeutics in Q2 2021 and held it in 14 quarters.
  • SignatureFD's iTeos Therapeutics position peaked at $76.4K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on SignatureFD's 13F filing for Q2 2025, filed 16 Jul 2025.